"nippon shinyaku" - Google News

Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug - statnews.com

Fri, 08 May 2026 07:00:00 GMT

Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug statnews.com

Aurora kinase B inhibitors disclosed in Nippon Shinyaku patent - BioWorld News

Tue, 16 Dec 2025 08:00:00 GMT

Aurora kinase B inhibitors disclosed in Nippon Shinyaku patent BioWorld News

Capricor sues partner Nippon Shinyaku in DMD therapy spat - pharmaphorum

Fri, 08 May 2026 07:00:00 GMT

Capricor sues partner Nippon Shinyaku in DMD therapy spat pharmaphorum

Nippon Shinyaku Co., Ltd. Proposes Year-End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 29, 2026 and Provides Dividend Guidance for the Second Quarter-End and Year-End Period of the Fiscal Year Ending March 31, 2027 - marketscreener.com

Sun, 07 Jun 2026 03:19:59 GMT

Nippon Shinyaku Co., Ltd. Proposes Year-End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 29, 2026 and Provides Dividend Guidance for the Second Quarter-End and Year-End Period of the Fiscal Year Ending March 31, 2027 marketscreener.com

Japan's Nippon Shinyaku partners with xFOREST Therapeutics on drug discovery research targeting RNA structures - BioSpectrum Asia

Tue, 14 Apr 2026 07:00:00 GMT

Japan's Nippon Shinyaku partners with xFOREST Therapeutics on drug discovery research targeting RNA structures BioSpectrum Asia

Nippon Shinyaku Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:NPPNY) 2026-05-15 - Seeking Alpha

Fri, 15 May 2026 07:00:00 GMT

Nippon Shinyaku Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:NPPNY) 2026-05-15 Seeking Alpha

FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis - PR Newswire

Tue, 09 Sep 2025 07:00:00 GMT

FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis PR Newswire

Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma - Fierce Pharma

Fri, 08 May 2026 07:00:00 GMT

Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma Fierce Pharma

Capricor seeks court intervention in fight over DMD cell therapy launch - FirstWord Pharma

Fri, 08 May 2026 07:00:00 GMT

Capricor seeks court intervention in fight over DMD cell therapy launch FirstWord Pharma

Should Lawsuit Over Deramiocel Deal and Gazyva Expansion Efforts Require Action From Nippon Shinyaku (TSE:4516) Investors? - simplywall.st

Sun, 17 May 2026 07:00:00 GMT

Should Lawsuit Over Deramiocel Deal and Gazyva Expansion Efforts Require Action From Nippon Shinyaku (TSE:4516) Investors? simplywall.st

Oct 30,2025 | Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults | News | CHUGAI PHARMACEUTICAL CO., LTD. - chugai-pharm.co.jp

Thu, 30 Oct 2025 07:00:00 GMT

Oct 30,2025 | Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults | News | CHUGAI PHARMACEUTICAL CO., LTD. chugai-pharm.co.jp

FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling - Fierce Biotech

Wed, 28 Jan 2026 08:00:00 GMT

FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling Fierce Biotech

FrieslandCampina Ingredients expands strategic partnership with Nippon Shinyaku in Japan - Dairy Business Middle East & Africa

Mon, 12 Jan 2026 08:00:00 GMT

FrieslandCampina Ingredients expands strategic partnership with Nippon Shinyaku in Japan Dairy Business Middle East & Africa

What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout

Fri, 13 Mar 2026 04:55:11 GMT

What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey Kavout

Capricor drops following filing of lawsuit against Nippon Shinyaku - Seeking Alpha

Fri, 08 May 2026 07:00:00 GMT

Capricor drops following filing of lawsuit against Nippon Shinyaku Seeking Alpha

Nippon Shinyaku Co., Ltd.: - marketscreener.com

Sun, 29 Mar 2026 07:00:00 GMT

Nippon Shinyaku Co., Ltd.: marketscreener.com

NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases - PR Newswire

Tue, 01 Jul 2025 07:00:00 GMT

NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases PR Newswire

Nippon Shinyaku Co., Ltd. Provides Consolidated Earnings Guidance for the First-Half Period and Full Year Fiscal Year Ending March 31, 2027 - marketscreener.com

Thu, 14 May 2026 07:00:00 GMT

Nippon Shinyaku Co., Ltd. Provides Consolidated Earnings Guidance for the First-Half Period and Full Year Fiscal Year Ending March 31, 2027 marketscreener.com

Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku - BioSpace

Tue, 14 Jan 2025 08:00:00 GMT

Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku BioSpace

Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku - BioPharma Dive

Tue, 14 Jan 2025 08:00:00 GMT

Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku BioPharma Dive

Nippon Shinyaku to pay $36M to reserve US rights to AB2 Bio's near-approval autoimmune drug - Fierce Biotech

Mon, 27 Jan 2025 08:00:00 GMT

Nippon Shinyaku to pay $36M to reserve US rights to AB2 Bio's near-approval autoimmune drug Fierce Biotech

Atsena Therapeutics and Nippon Shinyaku enter exclusive license agreement for ATSN-101 - Ophthalmology Times

Wed, 13 Nov 2024 08:00:00 GMT

Atsena Therapeutics and Nippon Shinyaku enter exclusive license agreement for ATSN-101 Ophthalmology Times

Nippon Shinyaku’s DMD drug fails confirmatory trial - pharmaphorum

Tue, 28 May 2024 07:00:00 GMT

Nippon Shinyaku’s DMD drug fails confirmatory trial pharmaphorum

Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial - statnews.com

Mon, 27 May 2024 07:00:00 GMT

Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial statnews.com

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - PR Newswire

Mon, 10 Mar 2025 07:00:00 GMT

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment PR Newswire

Panel OKs first OTC sales of erectile dysfunction drug in Japan - The Japan Times

Fri, 19 Sep 2025 07:00:00 GMT

Panel OKs first OTC sales of erectile dysfunction drug in Japan The Japan Times

AB2 Bio and Nippon Shinyaku enter Tadekinig alfa licensing deal - Pharmaceutical Technology

Tue, 28 Jan 2025 08:00:00 GMT

AB2 Bio and Nippon Shinyaku enter Tadekinig alfa licensing deal Pharmaceutical Technology

Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches - Fierce Biotech

Wed, 18 Sep 2024 07:00:00 GMT

Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches Fierce Biotech

Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - Pharmaceutical Technology

Wed, 15 Jan 2025 08:00:00 GMT

Regenxbio and Nippon Shinyaku forge $810m gene therapy deal Pharmaceutical Technology

NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization - PR Newswire

Wed, 10 Jul 2024 07:00:00 GMT

NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization PR Newswire

Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku - PR Newswire

Wed, 10 Nov 2021 08:00:00 GMT

Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku PR Newswire

Swiss AB2 Bio inks US$ 686m license option deal with Nippon Shinyaku - European Biotechnology Magazine

Mon, 27 Jan 2025 08:00:00 GMT

Swiss AB2 Bio inks US$ 686m license option deal with Nippon Shinyaku European Biotechnology Magazine

Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies - Contract Pharma

Wed, 15 Jan 2025 08:00:00 GMT

Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies Contract Pharma

Capricor Therapeutics and Nippon Shinyaku Enter Partnership - GlobeNewswire

Tue, 25 Jan 2022 08:00:00 GMT

Capricor Therapeutics and Nippon Shinyaku Enter Partnership GlobeNewswire

Nippon Shinyaku Owes Sarepta $115 Million in Patent Verdict (2) - Bloomberg Law News

Fri, 20 Dec 2024 08:00:00 GMT

Nippon Shinyaku Owes Sarepta $115 Million in Patent Verdict (2) Bloomberg Law News

Hidden genetic mismatch, which triples the risk of a life-threatening immune attack after cord blood transplantation - EurekAlert!

Fri, 20 Feb 2026 08:00:00 GMT

Hidden genetic mismatch, which triples the risk of a life-threatening immune attack after cord blood transplantation EurekAlert!

FDA Clears NS-050/NCNP-03 for Phase 1/2 Trial of Duchenne Muscular Dystrophy - NeurologyLive

Fri, 04 Aug 2023 07:00:00 GMT

FDA Clears NS-050/NCNP-03 for Phase 1/2 Trial of Duchenne Muscular Dystrophy NeurologyLive

AB2 Bio signs licensing agreement worth $500 M with Nippon Shinyaku for ultra-rare autoimmune disease treatment - BioSpectrum Asia

Tue, 28 Jan 2025 08:00:00 GMT

AB2 Bio signs licensing agreement worth $500 M with Nippon Shinyaku for ultra-rare autoimmune disease treatment BioSpectrum Asia

Capricor Therapeutics Signs Binding Term Sheet with Nippon - GlobeNewswire

Tue, 17 Sep 2024 07:00:00 GMT

Capricor Therapeutics Signs Binding Term Sheet with Nippon GlobeNewswire

NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial - BioSpace

Tue, 28 May 2024 07:00:00 GMT

NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial BioSpace

Nippon Shinyaku-Koku Office / Reiichi Ikeda Design - ArchDaily

Wed, 06 Oct 2021 07:00:00 GMT

Nippon Shinyaku-Koku Office / Reiichi Ikeda Design ArchDaily

AB2 Bio signs USD 600 million agreement with Nippon Shinyaku - Startupticker.

Mon, 27 Jan 2025 08:00:00 GMT

AB2 Bio signs USD 600 million agreement with Nippon Shinyaku Startupticker.

Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan - GlobeNewswire

Tue, 19 Mar 2019 07:00:00 GMT

Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan GlobeNewswire

UWA professor hooked into US blue between drug developers - The West Australian

Sun, 13 Aug 2023 07:00:00 GMT

UWA professor hooked into US blue between drug developers The West Australian

Urja Global: The strange case of a non-existent element and a market scam - CNBC TV18

Thu, 19 May 2022 07:00:00 GMT

Urja Global: The strange case of a non-existent element and a market scam CNBC TV18

Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy - TipRanks

Thu, 14 May 2026 07:00:00 GMT

Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy TipRanks